Patents by Inventor Siegfried Leistner

Siegfried Leistner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha
    Publication number: 20120094987
    Abstract: The invention relates to compounds of general formula (I); 1a, 1b, 1c and 1d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNF?-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
    Type: Application
    Filed: October 3, 2011
    Publication date: April 19, 2012
    Inventors: Claudia Reichelt, Alexander Ludwig, Alexander Schulze, Mohammed Daghish, Siegfried Leistner, Andreas Krödel, Jochen Heinicke
  • Substituted pyrido [3?, 2?: 4, 5] thieno [3, 2-D] pyrimidines and pyrido [3?, 2?: 4, 5] furo [3, 2-D] pyrimidines used as inhibitors of the PDE-4 and/or the release of TNF-ALPHA
    Patent number: 8058285
    Abstract: The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNF?-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: November 15, 2011
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Claudia Reichelt, Alexander Ludwig, Alexander Schulze, Mohammed Daghish, Siegfried Leistner, Andreas Krödel, Jochen Heinicke
  • SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA
    Publication number: 20080160028
    Abstract: The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNF?-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
    Type: Application
    Filed: January 22, 2007
    Publication date: July 3, 2008
    Inventors: Claudia Reichelt, Alexander Ludwig, Alexander Schulze, Mohammed Daghish, Siegfried Leistner, Andreas Krodel, Jochen Heinicke
  • Polycyclic pyrimidine -2,4(1H,3H)-diones with functionalized alkyl residues at the 1- and/or 3-position(s); methods for their synthesis and pharmaceutical preparation
    Patent number: 6872727
    Abstract: Polycyclic pyrimidine-2,4(1H,3H)-diones with functionalized alkyl residues at the 1-, the 3-, or both position(s); methods for their synthesis, production, and pharmaceutical preparation. The invention concerns the synthesis of the above-described compounds, their chemical and structural characterization, and the analysis of their physiological/pharmacological activities in vitro and in vivo. These goals have been attained by the specification of routes of synthesis, methods for the production of the compounds, and the presentation of compound-specific characteristics. The substances encompassed by the present invention demonstrate pharmacologically significant collangenase/matrix metalloproteinase inhibitory activities. The specific example 1-(3-mercaptoprop-1-yl)-3-methyl-chinazolin-2,4(1H,3H)-dione will be presented in detail.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: March 29, 2005
    Assignee: Privates Institut fur Biomedizinische Forschung und Beratung
    Inventors: Konrad Herrmann, Siegfried Leistner, Petra Wippich
  • 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
    Publication number: 20040044013
    Abstract: It is the object of this invention to discover and study new chemical substances of non-proteinogenic structure which have a matrix metalloproteinase (MMP)-inhibitory effect.
    Type: Application
    Filed: October 22, 2003
    Publication date: March 4, 2004
    Inventors: Jochen Heinicke, Uwe Klausmeier, Christoph Arkona, Siegfried Leistner
  • 3-(mercaptoalkyl)quinazoline
    Patent number: 5306721
    Abstract: A compound or its tautomer of Formula I, ##STR1## wherein R.sup.1 is hydrogen, a 6-methyl, 6-fluoro, 6-chloro, 6-bromo, or 6,7-dimethoxy residue,R.sup.2 is hydrogen, or a methyl residue,and n is 1 or 2,and tautomers and their pharmaceutically acceptable alkali, or ammonium salts.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: April 26, 1994
    Assignee: Arzneimittelerk Dresden G.m.b.H.
    Inventors: Siegfried Leistner, Michael Gutschow, Karl Drossler, Helmut Vieweg, Gunther Wagner, Thomas Strohscheidt, Dieter Lohmann, Gunter Laban, Herwart Ambrosius, Angela Siegling